Fulcrum Therapeutics Announces Topline Results from Phase 3 REACH Clinical Trial of ...
Losmapimod failed to improve reachable workspace (RWS) in FSHD patients at week 48, leading Fulcrum to suspend its development. Despite this, Fulcrum maintains a robust cash position to advance other therapies, including pociredir for sickle cell disease.
Related Clinical Trials
Highlighted Terms
Related News
Losmapimod, an investigational medication from Fulcrum Therapeutics, failed to significantly outperform a placebo in improving upper limb function and other clinical measures in people with facioscapulohumeral muscular dystrophy (FSHD) in the REACH Phase 3 trial. The company plans to stop developing losmapimod and focus on other clinical programs.
Fulcrum Therapeutics' experimental drug losmapimod failed a Phase 3 trial for muscular dystrophy FSHD, leading to suspension of its development. Despite positive signs in previous tests, losmapimod missed its main objective and secondary goals. Fulcrum's shares dropped 60%, and the company will focus on its sickle cell disease treatment, expecting Phase 1 data next year. The FDA previously suspended testing of the sickle cell therapy for six months.
Losmapimod failed to improve reachable workspace (RWS) in FSHD patients at week 48, leading Fulcrum to suspend its development. Despite this, Fulcrum maintains a robust cash position to advance other therapies, including pociredir for sickle cell disease.
Fulcrum Therapeutics' stock dropped >60% after its Phase 3 REACH trial for losmapimod, a potential FSHD treatment, missed its primary endpoint, leading to the suspension of the program.